A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo

Journal of Translational Medicine

Volumn 5, Issue , 2007, Pages

  Bhaskar, Vinay ^a   Zhang, Dong ^a   Fox, Melvin ^a   Seto, Pui ^a   Wong, Melanie H L ^a   Wales, Pauline E ^a   Powers, David ^a   Chao, Debra T ^a   DuBridge, Robert B ^a   Ramakrishnan, Vanitha ^a  

^a PDL BioPharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CROSS REACTING ANTIBODY; FIBRONECTIN; HETERODIMER; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VERY LATE ACTIVATION ANTIGEN 5 MONOCLONAL ANTIBODY; VOLOCIXIMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; LIPOCORTIN 5; MONOCLONAL ANTIBODY;

ANGIOSARCOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL DEATH; CELL MIGRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS REACTION; DRUG MECHANISM; DRUG POTENCY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HYBRIDOMA; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE MIGRATION INHIBITION TEST; MIGRATION INHIBITION; MOLECULAR CLONING; MOUSE; NONHUMAN; PROTEIN BINDING; RHABDOMYOSARCOMA; TUMOR XENOGRAFT; ANIMAL; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; MOUSE MUTANT; PLACENTA; PREGNANCY; RAT; SPRAGUE DAWLEY RAT; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANNEXIN A5; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL DEATH; CLONING, MOLECULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRONECTINS; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; INTEGRIN ALPHA5BETA1; MICE; MICE, SCID; PLACENTA; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION, HETEROLOGOUS;

EID: 39049171151     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-5-61     Document Type: Article

References (30)

1. Folkman J Tumor angiogenesis: Therapeutic implications N Engl J Med 1971, 285(21):1182-1186 4938153
2. Folkman J Merler E Abernathy C Williams G Isolation of a tumor factor responsible for angiogenesis J Exp Med 1971, 133(2):275-288 10.1084/ jem.133.2.275 4332371
3. Mendel DB Laird AD Xin X Louie SG Christensen JG Li G Schreck RE Abrams TJ Ngai TJ Lee LB Murray LJ Carver J Chan E Moss KG Haznedar JO Sukbuntherng J Blake RA Sun L Tang C Miller T Shirazian S McMahon G Cherrington JM In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 2003, 9(1):327-337 12538485
4. O'Farrell AM Abrams TJ Yuen HA Ngai TJ Louie SG Yee KW Wong LM Hong W Lee LB Town A Smolich BD Manning WC Murray LJ Heinrich MC Cherrington JM SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood 2003, 101(9):3597-3605 10.1182/ blood-2002-07-2307 12531805
5. Hotte SJ Hirte HW BAY 43-9006: Early clinical data in patients with advanced solid malignancies Curr Pharm Des 2002, 8(25):2249-2253 10.2174/ 1381612023393053 12369852
6. Wilhelm S Chien DS BAY 43-9006: Preclinical data Curr Pharm Des 2002, 8(25):2255-2257 10.2174/1381612023393026 12369853
7. Kabbinavar F Hurwitz HI Fehrenbacher L Meropol NJ Novotny WF Lieberman G Griffing S Bergsland E Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 2003, 21(1):60-65 10.1200/ JCO.2003.10.066 12506171
8. Kim KJ Li B Winer J Armanini M Gillett N Phillips HS Ferrara N Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 1993, 362(6423):841-844 10.1038/ 362841a0 7683111
9. Folkman J Fundamental concepts of the angiogenic process Curr Mol Med 2003, 3(7):643-651 10.2174/1566524033479465 14601638
10. John A Tuszynski G The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis Pathol Oncol Res 2001, 7(1):14-23 11349215
11. Giancotti FG Ruoslahti E Integrin signaling Science 1999, 285(5430):1028-1032 10.1126/science.285.5430.1028 10446041
12. Hynes RO Lively JC McCarty JH Taverna D Francis SE Hodivala-Dilke K Xiao Q The diverse roles of integrins and their ligands in angiogenesis Cold Spring Harb Symp Quant Biol 2002, 67:143-153 10.1101/sqb.2002.67.143 12858535
13. Lee BH Ruoslahti E alpha5beta1 integrin stimulates Bcl-2 expression and cell survival through Akt, focal adhesion kinase, and Ca2+/ calmodulin-dependent protein kinase IV J Cell Biochem 2005, 95(6):1214-1223 10.1002/jcb.20488 15962308
14. Mettouchi A Meneguzzi G Distinct roles of beta1 integrins during angiogenesis Eur J Cell Biol 2006, 85(3-4):243-247 10.1016/ j.ejcb.2005.09.010 16546568
15. Kim S Bakre M Yin H Varner JA Inhibition of endothelial cell survival and angiogenesis by protein kinase A J Clin Invest 2002, 110(7):933-941 151143 12370271 10.1172/JCI200214268
16. Kim S Bell K Mousa SA Varner JA Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin Am J Pathol 2000, 156(4):1345-1362 1876892 10751360
17. Khalili P Arakelian A Chen G Plunkett ML Beck I Parry GC Donate F Shaw DE Mazar AP Rabbani SA A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo Mol Cancer Ther 2006, 5(9):2271-2280 10.1158/1535-7163.MCT-06-0100 16985061
18. Maglott A Bartik P Cosgun S Klotz P Ronde P Fuhrmann G Takeda K Martin S Dontenwill M The small alpha5beta1 integrin antagonist, SJ749, reduces proliferation and clonogenicity of human astrocytoma cells Cancer Res 2006, 66(12):6002-6007 10.1158/0008-5472.CAN-05-4105 16778170
19. Sudhakar A Sugimoto H Yang C Lively J Zeisberg M Kalluri R Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins Proc Natl Acad Sci U S A 2003, 100(8):4766-4771 153630 12682293 10.1073/ pnas.0730882100
20. Yi M Ruoslahti E A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis Proc Natl Acad Sci U S A 2001, 98(2):620-624 14637 11209058 10.1073/pnas.98.2.620
21. Ramakrishnan V Bhaskar V Law DA Wong MH DuBridge RB Breinberg D O'Hara C Powers DB Liu G Grove J Hevezi P Cass KM Watson S Evangelista F Powers RA Finck B Wills M Caras I Fang Y McDonald D Johnson D Murray R Jeffry U Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent J Exp Ther Oncol 2006, 5(4):273-286 17024968
22. Bhaskar V Fox M Breinberg D Wong MH Wales PE Rhodes S Dubridge RB Ramakrishnan V Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits Invest New Drugs 2007 17786386
23. Baluk P Morikawa S Haskell A Mancuso M McDonald DM Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors Am J Pathol 2003, 163(5):1801-1815 1892429 14578181
24. Magnussen A Kasman IM Norberg S Baluk P Murray R McDonald DM Rapid access of antibodies to alpha5beta1 integrin overexpressed on the luminal surface of tumor blood vessels Cancer Res 2005 65 7 2712 2721 10.1158/0008-5472.CAN-04-2691 15805270
25. Tran Van Nhieu G Isberg RR Bacterial internalization mediated by beta 1 chain integrins is determined by ligand affinity and receptor density Embo J 1993, 12(5):1887-1895 413409 8491181
26. Afar DE Bhaskar V Ibsen E Breinberg D Henshall SM Kench JG Drobnjak M Powers R Wong M Evangelista F O'Hara C Powers D DuBridge RB Caras I Winter R Anderson T Solvason N Stricker PD Cordon-Cardo C Scher HI Grygiel JJ Sutherland RL Murray R Ramakrishnan V Law DA Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer Mol Cancer Ther 2004, 3(8):921-932 15299075
27. Bhaskar V Law DA Ibsen E Breinberg D Cass KM DuBridge RB Evangelista F Henshall SM Hevezi P Miller JC Pong M Powers R Senter P Stockett D Sutherland RL von Freeden-Jeffry U Willhite D Murray R Afar DE Ramakrishnan V E-selectin up-regulation allows for targeted drug delivery in prostate cancer Cancer Res 2003, 63(19):6387-6394 14559828
28. Goh KL Yang JT Hynes RO Mesodermal defects and cranial neural crest apoptosis in alpha5 integrin-null embryos Development 1997, 124(21):4309-4319 9334279
29. Glade-Bender J Kandel JJ Yamashiro DJ VEGF blocking therapy in the treatment of cancer Expert Opin Biol Ther 2003, 3(2):263-276 10.1517/ 14712598.3.2.263 12662141
30. Ranieri G Patruno R Ruggieri E Montemurro S Valerio P Ribatti D Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic Curr Med Chem 2006, 13(16):1845-1857 10.2174/092986706777585059 16842197